Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Evaluating the Utilization of All- T rans Retinoic Acid and Arsenic Trioxide during Consolidation Therapy for Patients Receiving Treatment for Acute Promyelocytic Leukemia

Laura A Bowers, PharmD, Maho Hibino, PharmD, Rebecca Garcia Hunt, PharmD, Leslie Renee Ellis, MD, Rupali Bhave, MD, Dianna S. Howard, MD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Timothy S. Pardee, MD PhD, Bayard L Powell, MD

Blood (2019) 134 (Supplement_1): 3901.

https://doi.org/10.1182/blood-2019-131817

Published: 2019

Journal Articles

Randomized Open-Labeled Academic Trial Comparing Standard AZA Therapy with Combination of G-CSF with AZA in High Risk MDS Patients - Interim Analysis

Anna Jonasova, MD PhD, Lubomir Minarik, MD, Vojtech Kulvait, PhD, Michal Pesta, PhD, Adel Schaffartzikova, MD, Galina Kislik, PhD, Nina Dusilkova, MD, Zuzana Zemanova, PhD, Tomas Stopka, MD PhD

Blood (2019) 134 (Supplement_1): 1729.

https://doi.org/10.1182/blood-2019-124274

Published: 2019

Journal Articles

Safety of Intravenous Arginine Therapy in Children with Sickle Cell Disease Hospitalized for Vaso-Occlusive Pain: A Randomized Placebo-Controlled Trial in Progress

Claudia R. Morris, MD, Janet Figueroa, MPH, Amanda Watt, Kirshma Khemani, MD, Polly Kumari, MBBS, Morgan Barnett, MPH, Nitya Bakshi, MBBS, MS, Peter A. Lane, MD, Carlton Dampier, MD

Blood (2019) 134 (Supplement_1): 995.

https://doi.org/10.1182/blood-2019-122983

Published: 2019

Journal Articles

Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B model

Brian Cooley, George J. Broze, Jr, David M. Mann, Feng-Chang Lin, Lee G. Pedersen, Darrel W. Stafford

Blood (2019) 133 (22): 2445–2451.

https://doi.org/10.1182/blood.2018884015

Published: 2019

Journal Articles

Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B - 1 Year Follow up and Impact of Baseline Characteristics on Transgene-Derived Factor IX Activity and Persistence

Blood (2017) 130 (Supplement 1): 601.

https://doi.org/10.1182/blood.V130.Suppl_1.601.601

Published: 2017

Journal Articles

A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma

Peter Martin, MD, Nancy L. Bartlett, MD, Ildefonso Ismael Rodriguez Rivera, MD, Maria Revuelta, PhD, Julio C. Chavez, MD, John L. Reagan, MD, Sonali M. Smith, MD, Ann S. LaCasce, MD, Lei Zhang, MD, Merry Zhai, BS, Chengqing Wu, PhD, John P. Leonard, MD, Leandro Cerchietti, MD

Blood (2017) 130 (Supplement 1): 192.

https://doi.org/10.1182/blood.V130.Suppl_1.192.192

Published: 2017

Journal Articles

Inhibition of Nucleocytoplasmic Export Enhances Selective Elimination of Leukemic Stem Cells in Chronic Myeloid Leukemia

Hein Than, MD FRCPath, MRCP, Anthony D. Pomicter, MS, Clinton C. Mason, PhD, Anna M. Eiring, PhD, William L. Heaton, MS, Dongqing Yan, Anna Senina, MS, Phillip M. Clair, MS, Tessa L. Holyoake, MD PhD FRCP, FRCPath, Thomas O'Hare, PhD, Michael W. Deininger, MD PhD

Blood (2017) 130 (Supplement 1): 42.

https://doi.org/10.1182/blood.V130.Suppl_1.42.42

Published: 2017

Journal Articles

Combined Azacitidine and High Dose Lenalidomide Therapy Is Well Tolerated and Clinically Active in Patients Who Relapse after Allogeneic Stem Cell Transplantation for Actue Myeloid Leukemia: Results of the Uk Trials Acceleration Programme Viola Trial

Charles Craddock, Wendy Ingram, Daniel Slade, Andrea Hodgkinson, BSc(Hons),PhD, Francis J. Mussai, MA, MD DPhil, Carmela De Santo, Jamie Cavenagh, Michael Dennis, MDMRCP,FRCPath, Ram Malladi, MRCP, FRCPath, PhD, Shamyla Siddique, BSc.(Hons.), MPhil, Yap Christina, MSci, PhD CStat

Blood (2017) 130 (Supplement 1): 276.

https://doi.org/10.1182/blood.V130.Suppl_1.276.276

Published: 2017

Journal Articles

"Direct to Drug" Screening As a Route to Individualized Therapy in Multiple Myeloma

Nathalie Meurice, PhD, Joachim L Petit, PhD, Cecilia Bonolo De Campos, PhD, Alysia N Polito, BS, Ilsel D Lopez Armenta, BS, Gregory J Ahmann, BS, Laura Ann Bruins, BS, Joseph R Mikhael, MD FRCPC, MD, Craig B. Reeder, MD, Angela A Mayo, MS, PA-C, P. Leif Bergsagel, MD, Rafael Fonseca, MD, Nikolai Sepetov, PhD, Sergei Romanov, PhD, A. Keith Stewart, MBChB, MBA

Blood (2017) 130 (Supplement 1): 3080.

https://doi.org/10.1182/blood.V130.Suppl_1.3080.3080

Published: 2017

Journal Articles

Selective Inhibition of Nucleocytoplasmic Transport Overcomes Ruxolitinib Resistance in Myelofibrosis

Dongqing Yan, Srinivas K. Tantravahi, MBBS, Anthony D. Pomicter, MS, Clinton C. Mason, PhD, Anna Senina, MS, Qiang Wang, PhD, Jamshid Sorouri Khorashad, MD PhD FRCPath, Hein Than, MD FRCPath, MRCP, Phillip M. Clair, MS, William L. Heaton, MS, Anna M. Eiring, PhD, Josef T. Prchal, MD, Sabina I. Swierczek, PhD, Erkan Baloglu, Sharon Shacham, PhD MBA, Thomas O'Hare, PhD, Michael W. Deininger, MD PhD

Blood (2017) 130 (Supplement 1): 1660.

https://doi.org/10.1182/blood.V130.Suppl_1.1660.1660

Published: 2017

Journal Articles

Prolonged Arsenic Trioxide (ATO) and All- Trans Retinoic Acid (ATRA) Therapy for Relapsed Acute Promyelocytic Leukemia

Laura Cicconi, Massimo Breccia, MD, PhD, Luca Franceschini, MD, PhD, Roberto Latagliata, Matteo Molica, MD, Manuela Rizzo, MD, Mariadomenica Divona, BS, Licia Iaccarino, BS, Tiziana Ottone, PhD, Valentina Alfonso, BS, Robin Foa, MD, Maria Teresa Voso, MD, Francesco Lo Coco, MD

Blood (2017) 130 (Supplement 1): 147.

https://doi.org/10.1182/blood.V130.Suppl_1.147.147

Published: 2017

Journal Articles

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

Blood (2017) 130 (Supplement 1): 1377.

https://doi.org/10.1182/blood.V130.Suppl_1.1377.1377

Published: 2017

Journal Articles

A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies

Gautam Borthakur, MD, Mark A Dawson, MD PhD, Eytan M. Stein, MD, Anastasios Karadimitris, Brian J.P Huntly, MD PhD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Aristeidis Chaidos, Thierry Horner, PhD, John Brennan, January Baron, Brandon E. Kremer, MD PhD, Arindam Dhar, MBBS, MD PhD

Blood (2016) 128 (22): 5223.

https://doi.org/10.1182/blood.V128.22.5223.5223

Published: 2016

Journal Articles

Selective Inhibition of Nuclear Cytoplasmic Transport As a New Treatment Paradigm in Myelofibrosis

Dongqing Yan, PhD, Srinivas K. Tantravahi, MD, Anthony D. Pomicter, MS, Anna Senina, MS, Kevin C. Gantz, Hannah M. Redwine, Josef T. Prchal, MD, Sabina Swierczek, PhD, Phillip M. Clair, MS, Anna M. Eiring, PhD, Erkan Baloglu, PhD MBA, Thomas O'Hare, PhD, Michael W. Deininger, MD PhD

Blood (2016) 128 (22): 636.

https://doi.org/10.1182/blood.V128.22.636.636

Published: 2016

Journal Articles

Persistence of Non Gene-Modified Adoptively Transferred Marrow Infiltrating Lymphocytes (MILs) More Than Five Years Post Transfer

Kimberly A Noonan, PhD MPH, Lakshmi Rudraraju, MS, Valentina Hoyos, MD, Eric Lutz, PhD, Ivan Borrello, MD

Blood (2016) 128 (22): 4552.

https://doi.org/10.1182/blood.V128.22.4552.4552

Published: 2016

Journal Articles

Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL)

Jianxiang Wang, MD PhD, Yingchang Mi, MD PhD, Bin Jiang, Xiequn Chen, Chunyan Ji, MD PhD, Yan Li, Xielan Zhao, Yongrong Lai, Yu Hu, MD, PhD, Aiping Tang, Ting Liu, MDPhD, Jie Jin, MD PhD, Junmin Li, Linhua Yang, Jianyong Li, MD PhD, Fanyi Meng

Blood (2015) 126 (23): 220.

https://doi.org/10.1182/blood.V126.23.220.220

Published: 2015

Journal Articles

ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia: Preliminary Results from a Phase 1 Open-Label, Dose-Escalation Study

Tomoki Naoe, MD PhD, Toru Sakura, MD PhD, Yukio Kobayashi, MD PhD, Kensuke Usuki, MDPhD, Toshihiro Miyamoto, MD PhD, Hiroatsu Iida, MD PhD, Satoshi Morita, PhD, Erkut Bahceci, MD, Masahito Kaneko, RPh, Shunsuke Yamada, M.Eng, Shigeru Takeshita, MSc, Shuichi Miyawaki, MDPhD

Blood (2015) 126 (23): 1320.

https://doi.org/10.1182/blood.V126.23.1320.1320

Published: 2015

Journal Articles

Impact of Hypomethylating Agent Therapy in Myelodysplastic Syndromes with Chromosome 3 Abnormalities

David Sallman, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, Mikkael A. Sekeres, MD MS, Amy E. DeZern, MD MHS, David P. Steensma, MD, Gail J. Roboz, MD, John Barnard, PhD, Najla H. Al Ali, BDS, MSc, Cassie Zimmerman, MPH, Sherry Pierce, BSN, BA, Denise Batista, PhD, Jeffrey E Lancet, MD, Eric Padron, MD, Jaroslaw P. Maciejewski, MD PhD, Alan F. List, MD, Hagop M. Kantarjian, MD, Rami S. Komrokji, MD

Blood (2015) 126 (23): 1705.

https://doi.org/10.1182/blood.V126.23.1705.1705

Published: 2015

Journal Articles

The intron-22–inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics

Zuben E. Sauna, Jay N. Lozier, Carol K. Kasper, Chen Yanover, Timothy Nichols, Tom E. Howard

Blood (2015) 125 (2): 223–228.

https://doi.org/10.1182/blood-2013-12-530113

Published: 2015

Journal Articles

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

Madeleine Duvic, MD, Timothy M Kuzel, MD, Nam H. Dang, MD PhD, Miles Prince, MD FRACP, FRCPA, Tatyana Feldman, MD, Francine M. Foss, MD, Matthew Guo, PhD, Lone Harild Ottesen, MD PhD, Chean Eng Ooi, PhD, Youn H Kim, MD

Blood (2014) 124 (21): 3097.

https://doi.org/10.1182/blood.V124.21.3097.3097

Published: 2014

NARROW

Evaluating the Utilization of All- T rans Retinoic Acid and Arsenic Trioxide during Consolidation Therapy for Patients Receiving Treatment for Acute Promyelocytic Leukemia

Randomized Open-Labeled Academic Trial Comparing Standard AZA Therapy with Combination of G-CSF with AZA in High Risk MDS Patients - Interim Analysis

Safety of Intravenous Arginine Therapy in Children with Sickle Cell Disease Hospitalized for Vaso-Occlusive Pain: A Randomized Placebo-Controlled Trial in Progress

Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B model

Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B - 1 Year Follow up and Impact of Baseline Characteristics on Transgene-Derived Factor IX Activity and Persistence

A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma

Inhibition of Nucleocytoplasmic Export Enhances Selective Elimination of Leukemic Stem Cells in Chronic Myeloid Leukemia

Combined Azacitidine and High Dose Lenalidomide Therapy Is Well Tolerated and Clinically Active in Patients Who Relapse after Allogeneic Stem Cell Transplantation for Actue Myeloid Leukemia: Results of the Uk Trials Acceleration Programme Viola Trial

"Direct to Drug" Screening As a Route to Individualized Therapy in Multiple Myeloma

Selective Inhibition of Nucleocytoplasmic Transport Overcomes Ruxolitinib Resistance in Myelofibrosis

Prolonged Arsenic Trioxide (ATO) and All- Trans Retinoic Acid (ATRA) Therapy for Relapsed Acute Promyelocytic Leukemia

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies

Selective Inhibition of Nuclear Cytoplasmic Transport As a New Treatment Paradigm in Myelofibrosis

Persistence of Non Gene-Modified Adoptively Transferred Marrow Infiltrating Lymphocytes (MILs) More Than Five Years Post Transfer

Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL)

ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia: Preliminary Results from a Phase 1 Open-Label, Dose-Escalation Study

Impact of Hypomethylating Agent Therapy in Myelodysplastic Syndromes with Chromosome 3 Abnormalities

The intron-22–inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only